ND Biosciences was founded to develop next-generation therapeutics and diagnostics for neurodegenerative diseases (NDs).

The therapies developed at ND Biosciences focus on treating both
early and late stages of NDs. This is accomplished by developing
combination therapies that prevent the initiation of pathological
protein aggregation observed in NDs, and that neutralize the activities
of existing protein aggregates.

ND Biosciences has developed integrated proprietary platforms that
enable its transformative drug discovery and preclinical development
programs. These platforms are based on unique capabilities and model
systems that allow ND Biosciences to:

1. Reverse-engineer the complexity of protein aggregates observed in NDs under controlled conditions
2. Model key processes underlying the formation of protein pathologies and neurodegeneration in living neurons
3. Develop novel companion diagnostic assays and imaging agents that capture the diversity and complexity of protein pathology in patient’s brains